Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$8.37
$8.37
$2.66
$8.55
$401.26M0.522.97 million shsN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$1.23
+1.7%
$1.42
$0.72
$6.77
$14.75M0.8981,984 shs20,378 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$12.35
-0.2%
$8.45
$6.53
$30.60
$108.11M2.75132,460 shs90,045 shs
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$2.69
-2.2%
$2.27
$1.46
$4.10
N/A0.1944,307 shs8,218 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00%-1.63%-20.92%+63.51%-76.24%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+6.72%+14.00%+51.90%+6.61%-39.31%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
+5.77%+14.58%+24.43%+46.28%-2.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.4055 of 5 stars
3.25.00.00.00.01.70.6
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.5781 of 5 stars
2.92.00.04.62.80.80.0
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
1.8775 of 5 stars
0.05.00.04.20.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera AG stock logo
BFRA
Biofrontera
0.00
N/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00
N/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.33
Hold$4.50265.85% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67496.49% Upside
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest CNCE, BFRA, MCRB, HOOK, and MEIP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$32.58M12.32N/AN/A$3.24 per share2.58
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$43.95M0.34N/AN/A$4.25 per share0.29
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M0.85N/AN/A$1.61 per share7.67
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$65.30MN/A$5.85 per share0.46$4.96 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$43.50M-$5.850.00N/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$17.78M-$4.750.00N/AN/AN/A-77.00%-64.79%9/17/2025 (Estimated)

Latest CNCE, BFRA, MCRB, HOOK, and MEIP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A
5/13/2025Q3 2025
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A-$0.39N/A-$0.39N/AN/A
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/A
9.03
9.03
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/A
3.61
3.61
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A
16.78
16.78

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
70.63%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
63.88%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
52.38%

Insider Ownership

CompanyInsider Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
N/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
11.33%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
3.30%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
3.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
6447.94 million42.51 millionOptionable
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
16012.19 million11.79 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million8.32 millionOptionable
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
100N/AN/AOptionable

Recent News About These Companies

MEI Pharma Registered Shs
MEI Pharma (NASDAQ:MEIP) Stock, Option Chain
MEI Pharma gets grant for compounds for treating proliferative diseases
MEI Pharma reviews strategic options amid fiscal changes
MEI Pharma Reports Fiscal Year End 2024 Cash Position
MEI Pharma Reports Fiscal Year End 2024 Cash Position
MEI Pharma To Begin Evaluation Of Strategic Alternatives - Quick Facts
MEI Pharma to Consider Strategic Alternatives

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Concert Pharmaceuticals stock logo

Concert Pharmaceuticals NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

HOOKIPA Pharma stock logo

HOOKIPA Pharma NASDAQ:HOOK

$1.23 +0.02 (+1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$1.23 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$12.35 -0.03 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$12.21 -0.14 (-1.13%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MEI Pharma stock logo

MEI Pharma NASDAQ:MEIP

$2.69 -0.06 (-2.18%)
Closing price 03:59 PM Eastern
Extended Trading
$2.70 +0.01 (+0.37%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.